Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | May 12, 2026 | May 14, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | SVP and CFO | March 01, 2022 | March 03, 2022 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Executive Vice President & CFO | July 22, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $533.92 · Expires 2036-05-11 | Direct | 525 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 525 · Balance 525 F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. |
| Deferred Stock UnitSEC Table II · derivative / convertible security | Direct | 1,354 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Grant · Acquired 234 · Balance 1,354 F2: Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.
F2: Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.
ILLUMINA, INC.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,297 |
Reported balance
After 2022-03-01 transaction · row 1
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 2,082 · Balance 11,297 F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2022, November 5, 2023, November 5, 2024, and November 5, 2025, subject to the awardee's continuing status as a service provider on such dates. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2024-12-29 | Direct | 6,246 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 6,246 · Balance 6,246 F2: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2022, November 5, 2023, November 5, 2024, and November 5, 2025, subject to the awardee's continuing status as a service provider on such dates.
F2: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates.
QUEST DIAGNOSTICS INC
Report date July 22, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,478 |
Reported balance
After 2026-07-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-22 · Grant · Acquired 102 · Balance 33,478 F1: Represents an award of restricted share units. F2: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted share units.
F2: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2021 Filed May 14, 2021 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-010256 · doc1.xml · derivative · entry 1 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887 Underlying: Common Stock · 224 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:51 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 4,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006524 · form4.xml · derivative · entry 4 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,379 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. F2 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:51 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 2,170 | $494.24 | $1,072,500.80 |
DisclosureSEC source: 0001127602-21-006524 · form4.xml · nonDerivative · entry 3 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,185 Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:51 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 4,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006524 · form4.xml · nonDerivative · entry 2 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:51 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 482 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006524 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,976 F1 · shares: Represents additional shares of stock awarded as a result of the Company achieving at least 111% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 23:56 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 4,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005287 · form4.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,140 Underlying: Common Stock · 4,140 shares Expires 2023-12-31 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 31, 2023. The number of shares issued will range from 0% to 175% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 31,2023, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 31, 2023. The number of shares issued will range from 0% to 175% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 31,2023, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 23:56 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005287 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,494 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2021, November 5, 2022, November 5, 2023, and November 5, 2024, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 22:51 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 214 | $376.55 | $80,581.70 |
DisclosureSEC source: 0001127602-21-001215 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,114 Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:53 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 551 | $311.72 | $171,757.72 |
DisclosureSEC source: 0001127602-20-028511 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,328 Read SEC document |
| May 26, 2020 Filed May 28, 2020 22:20 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,356 | $360.00 | $488,160.00 |
DisclosureSEC source: 0001127602-20-018090 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,879 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,357 | $340.00 | $461,380.00 |
DisclosureSEC source: 0001127602-20-017422 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,235 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 1,279 | Not disclosed Strike: $283.59 | Not disclosed |
DisclosureSEC source: 0001567619-20-009378 · doc1.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 Underlying: Common Stock · 1,279 shares Expires 2030-05-05 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-009378 · doc1.xml · derivative · entry 1 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 663 Underlying: Common Stock · 370 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. ( F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. ( F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. ( Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:54 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,356 | $320.02 | $433,947.12 |
DisclosureSEC source: 0001127602-20-014314 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,592 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 1,356 shares sold ranging from $320.00 to $320.11 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 21:41 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,697 | $300.00 | $509,100.00 |
DisclosureSEC source: 0001127602-20-014143 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,948 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 20:25 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 249 | $292.54 | $72,842.46 |
DisclosureSEC source: 0001127602-20-013857 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,645 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:09 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 6,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005390 · form4.xml · derivative · entry 4 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,626 shares Expires 2019-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on January 6, 2017. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on January 6, 2017. F2 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on January 6, 2017. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:09 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 4,513 | $296.00 | $1,335,848.00 |
DisclosureSEC source: 0001127602-20-005390 · form4.xml · nonDerivative · entry 3 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,894 Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:09 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 6,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005390 · form4.xml · nonDerivative · entry 2 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on January 6, 2017. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:09 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 3,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005390 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,781 F1 · shares: Represents additional shares of stock awarded as a result of the Company achieving at least 150% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on January 6, 2017. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:08 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 4,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004413 · form4.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 Underlying: Common Stock · 4,370 shares Expires 2023-01-01 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:08 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004413 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,468 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 5, 2021, February 5, 2022, February 5, 2023 and February 5, 2024, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:40 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 238 | $293.10 | $69,757.80 |
DisclosureSEC source: 0001127602-20-003813 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,011 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:09 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 212 | $325.53 | $69,012.36 |
DisclosureSEC source: 0001127602-20-001319 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,249 Read SEC document |
| November 29, 2019 Filed Dec 4, 2019 01:35 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 892 | $320.00 | $285,440.00 |
DisclosureSEC source: 0001127602-19-034199 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,461 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:44 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 259 | $300.87 | $77,925.33 |
DisclosureSEC source: 0001127602-19-032205 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,353 Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 21:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 1,025 | Not disclosed Strike: $289.74 | Not disclosed |
DisclosureSEC source: 0001567619-19-017893 · doc1.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025 Underlying: Common Stock · 1,025 shares Expires 2029-08-31 F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from his election to the IDEXX Laboratories, Inc. Board of Directors on July 16, 2019 until the 2020 annual meeting of stockholders. F3 · derivative.exercise_price: August 30, 2019 closing price of Issuer common stock on the NASDAQ Global Select Market. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 6, 2020. Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 21:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 293 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-017893 · doc1.xml · derivative · entry 1 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293 Underlying: Common Stock · 293 shares Expires not disclosed F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from his election to the IDEXX Laboratories, Inc. Board of Directors on July 16, 2019 until the 2020 annual meeting of stockholders. F2 · derivative.exercise_price: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F5 · price: Not applicable. F2 · derivative.exercise_date: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F2 · derivative.expiration_date: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 22:17 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 213 | $307.89 | $65,580.57 |
DisclosureSEC source: 0001127602-19-001641 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,612 Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 4,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036237 · form4.xml · derivative · entry 2 SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,561 Underlying: Common Stock · 4,561 shares Expires 2022-01-02 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036237 · form4.xml · nonDerivative · entry 1 SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,825 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2019, November 5, 2020, November 5, 2021 and November 5, 2022, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 22:33 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 127 | $324.14 | $41,165.78 |
DisclosureSEC source: 0001127602-18-032459 · form4.xml · nonDerivative · entry 1 SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,304 Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 23:10 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 238 | $227.06 | $54,040.28 |
DisclosureSEC source: 0001127602-18-001576 · form4.xml · nonDerivative · entry 1 SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,431 Read SEC document |
| December 11, 2017 Filed Dec 14, 2017 01:40 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 4,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-034606 · form4.xml · derivative · entry 2 SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,379 Underlying: Common Stock · 4,379 shares Expires 2021-01-03 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| December 11, 2017 Filed Dec 14, 2017 01:40 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-034606 · form4.xml · nonDerivative · entry 1 SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,669 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2018, November 5, 2019, November 5, 2020, and November 5, 2021, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| January 06, 2017 Filed Jan 13, 2017 01:36 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 6,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-001632 · form4.xml · derivative · entry 2 SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,626 Underlying: Common Stock · 6,626 shares Expires 2019-12-29 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2019. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 29, 2019, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F2 · shares: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2019. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 29, 2019, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2019. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 29, 2019, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| January 06, 2017 Filed Jan 13, 2017 01:36 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 2,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-001632 · form4.xml · nonDerivative · entry 1 SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,209 F1 · shares: Grant of restricted stock units with 25% of the shares subject to the award vesting on each of the first, second, third and fourth anniversaries of the date of grant, subject to the awardee's continuing to be a service provider on such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.